» Articles » PMID: 30227984

T2 Mapping MRI Technique Quantifies Carotid Plaque Lipid, and Its Depletion After Statin Initiation, Following Acute Myocardial Infarction

Overview
Journal Atherosclerosis
Publisher Elsevier
Date 2018 Sep 20
PMID 30227984
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: A recently-validated, highly-sensitive T2 mapping magnetic resonance (MRI) technique accurately quantifies carotid plaque lipid. The aims of this study were to determine: (i) the extent of carotid plaque lipid in patients with acute coronary syndromes (ACS); (ii) the effects of initiation of high-intensity statin on plaque lipid content and (iii) whether plaque lipid content is related to standard or 'functional' blood lipid measurements.

Methods: Statin naïve subjects presenting with ACS underwent carotid artery MRI at 3 T scanner to quantify plaque lipid. Patients were subsequently commenced on high dose statin as part of clinical care and underwent a second MRI after three months. Plaque composition was measured using objective semi-automated techniques.

Results: 23 out of 24 patients had measurable lipid. Three months after statin initiation there was a significant reduction in carotid lipid percentage [from 10.3% (7.2-14.2) to 7.4% (5.4-10.0), p = 0.002] and a significant increase in fibrous percentage [from 83.3% ± 6.6-85.5% ± 4.8, p = 0.039]. None of the studied functional blood biomarkers were related to either baseline carotid plaque lipid content or its propensity to change with statin treatment.

Conclusions: T2-mapping demonstrated depleted carotid plaque lipid following the initiation of high-intensity statin treatment. Standard or 'functional' blood biomarkers were dissociated from plaque lipid content or changes with treatment. These findings further reinforce the importance of disease characterisation over risk factor assessment. Subject to clinical trial findings, quantification of plaque lipid may provide the basis for an approach to identify patients suitable for intensive lipid reduction regimes.

Citing Articles

Atherosclerosis Residual Lipid Risk-Overview of Existing and Future Pharmacotherapies.

Omari M, Alkhalil M J Cardiovasc Dev Dis. 2024; 11(4).

PMID: 38667744 PMC: 11050263. DOI: 10.3390/jcdd11040126.


10-channel phased-array coil for carotid wall MRI at 3T.

de Buck M, Jezzard P, Frost R, Randell C, Hurst K, Choudhury R PLoS One. 2023; 18(8):e0288529.

PMID: 37556496 PMC: 10411804. DOI: 10.1371/journal.pone.0288529.


The Emerging Role of Icosapent Ethyl in Patients with Cardiovascular Disease: Mechanistic Insights and Future Applications.

Gupta A, Alkhalil M J Clin Med. 2023; 12(11).

PMID: 37297952 PMC: 10253987. DOI: 10.3390/jcm12113758.


Advances in Cardiovascular Pharmacology in Atherosclerotic-Related Therapeutic Areas: Addressing Patients' Clinical Needs.

Omari M, Alkhalil M J Clin Med. 2023; 12(11).

PMID: 37297860 PMC: 10253852. DOI: 10.3390/jcm12113665.


Inflammation, coronary plaque progression, and statin use: A secondary analysis of the Risk Stratification with Image Guidance of HMG CoA Reductase Inhibitor Therapy (RIGHT) study.

Scott C, Lateef S, Hong C, Dey A, Manyak G, Patel N Clin Cardiol. 2022; 45(6):622-628.

PMID: 35366378 PMC: 9175258. DOI: 10.1002/clc.23808.